Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ETI-204 in Healthy Subjects

NCT01453907 is registered in ClinicalTrials.gov with Elusys Therapeutics as lead sponsor.

NCT NCT01453907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01453907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ETI-204 in Healthy Subjects
Lead sponsor
Elusys Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2011
Completion date
December 31, 2012
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anthrax